CRISPR Therapeutics Stock Rises Despite Broader Losses, But Faces Uncertainty Ahead
• CRISPR Therapeutics (CRSP) stock closed higher despite market losses, but shares are down 20% over the past month
• CRISPR is expected to report a steep drop in earnings and revenue in its next quarterly report
• Analysts have revised earnings estimates slightly upward recently, signaling optimism about the company
• CRISPR currently has a Zacks Rank of #3 (Hold), putting it in the top 29% of Zacks-ranked industries
• Zacks recommends keeping an eye on metrics like estimate revisions to gauge near-term stock momentum for companies like CRISPR